Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes
Purpose This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes. Methods Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cance...
Gespeichert in:
| Veröffentlicht in: | Cancer causes & control 2019-05, Vol.30 (5), p.417-424 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 424 |
|---|---|
| container_issue | 5 |
| container_start_page | 417 |
| container_title | Cancer causes & control |
| container_volume | 30 |
| creator | Parise, Carol A. Caggiano, Vincent |
| description | Purpose
This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes.
Methods
Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2− subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2−.
Results
The odds of TP versus ER+/PR+/HER2− were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40–1.55), black (OR 1.11; CI 1.02–1.21), Asian/Pacific Islander (OR 1.15; CI 1.09–1.22), and uninsured (OR 1.42; CI 1.15–1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2− subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2− subtype.
Conclusions
Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2− subtype. However the risk of mortality between these two subtypes is similar. |
| doi_str_mv | 10.1007/s10552-019-01152-8 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2193604991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>48691292</jstor_id><sourcerecordid>48691292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-5f0420feee017b5177164f538cc873c803ff0bc0ea2249e348b27760b2678f443</originalsourceid><addsrcrecordid>eNp9kc9qFEEQxhtRzBp9AUFp8CLImOp_09NHSVYjBJSg56GnU53tdXZm7O5R9pYH8OYb-iR2MjGCBw9FFdTv-6rgI-Qpg9cMQB8lBkrxCpgpxcrU3CMrprSoNOfqPlmBUbpSXIoD8iilLQComsNDciCg0YaDWpEfJ8F7jDg4TDQM1PVhCG6cbN6M_WVw1G1stC5jDCkHl6gdLmiZv9DR090Ys-1D3tMO83fEgeYN0hzD1COdxhRy-IY3ivX5q6OPpU7X5_zX1U_aRbQpU2fL3UjT3OX9hOkxeeBtn_DJbT8kn9-uPx2fVmcf3r0_fnNWOWF0rpQHycEjIjDdKaY1q6VXonGu0cI1ILyHzgFazqVBIZuOa11Dx2vdeCnFIXm5-E5x_Dpjyu0uJId9bwcc59RyZkQN0hhW0Bf_oNtxjkP57ppiRjJgUCi-UC6OKUX07RTDzsZ9y6C9zqpdsmpLVu1NVm1TRM9vreduhxd3kj_hFEAsQCqr4RLj39v_tX22qLYpj_HOVTa1Ydxw8RvlSqmY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191941010</pqid></control><display><type>article</type><title>Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes</title><source>JSTOR Archive Collection A-Z Listing</source><source>SpringerLink Journals - AutoHoldings</source><creator>Parise, Carol A. ; Caggiano, Vincent</creator><creatorcontrib>Parise, Carol A. ; Caggiano, Vincent</creatorcontrib><description>Purpose
This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes.
Methods
Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2− subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2−.
Results
The odds of TP versus ER+/PR+/HER2− were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40–1.55), black (OR 1.11; CI 1.02–1.21), Asian/Pacific Islander (OR 1.15; CI 1.09–1.22), and uninsured (OR 1.42; CI 1.15–1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2− subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2− subtype.
Conclusions
Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2− subtype. However the risk of mortality between these two subtypes is similar.</description><identifier>ISSN: 0957-5243</identifier><identifier>EISSN: 1573-7225</identifier><identifier>DOI: 10.1007/s10552-019-01152-8</identifier><identifier>PMID: 30879205</identifier><language>eng</language><publisher>Cham: Springer Science + Business Media</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Cancer ; Cancer Research ; Demographics ; Epidemiology ; ErbB-2 protein ; Health risk assessment ; Health risks ; Hematology ; Invasiveness ; Mortality ; Oncology ; ORIGINAL PAPER ; Public Health ; Regression analysis ; Risk ; Survival ; Survival analysis</subject><ispartof>Cancer causes & control, 2019-05, Vol.30 (5), p.417-424</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Cancer Causes & Control is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-5f0420feee017b5177164f538cc873c803ff0bc0ea2249e348b27760b2678f443</citedby><cites>FETCH-LOGICAL-c397t-5f0420feee017b5177164f538cc873c803ff0bc0ea2249e348b27760b2678f443</cites><orcidid>0000-0002-3098-6160</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/48691292$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/48691292$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,41488,42557,51319,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30879205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parise, Carol A.</creatorcontrib><creatorcontrib>Caggiano, Vincent</creatorcontrib><title>Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes</title><title>Cancer causes & control</title><addtitle>Cancer Causes Control</addtitle><addtitle>Cancer Causes Control</addtitle><description>Purpose
This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes.
Methods
Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2− subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2−.
Results
The odds of TP versus ER+/PR+/HER2− were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40–1.55), black (OR 1.11; CI 1.02–1.21), Asian/Pacific Islander (OR 1.15; CI 1.09–1.22), and uninsured (OR 1.42; CI 1.15–1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2− subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2− subtype.
Conclusions
Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2− subtype. However the risk of mortality between these two subtypes is similar.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Demographics</subject><subject>Epidemiology</subject><subject>ErbB-2 protein</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Hematology</subject><subject>Invasiveness</subject><subject>Mortality</subject><subject>Oncology</subject><subject>ORIGINAL PAPER</subject><subject>Public Health</subject><subject>Regression analysis</subject><subject>Risk</subject><subject>Survival</subject><subject>Survival analysis</subject><issn>0957-5243</issn><issn>1573-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc9qFEEQxhtRzBp9AUFp8CLImOp_09NHSVYjBJSg56GnU53tdXZm7O5R9pYH8OYb-iR2MjGCBw9FFdTv-6rgI-Qpg9cMQB8lBkrxCpgpxcrU3CMrprSoNOfqPlmBUbpSXIoD8iilLQComsNDciCg0YaDWpEfJ8F7jDg4TDQM1PVhCG6cbN6M_WVw1G1stC5jDCkHl6gdLmiZv9DR090Ys-1D3tMO83fEgeYN0hzD1COdxhRy-IY3ivX5q6OPpU7X5_zX1U_aRbQpU2fL3UjT3OX9hOkxeeBtn_DJbT8kn9-uPx2fVmcf3r0_fnNWOWF0rpQHycEjIjDdKaY1q6VXonGu0cI1ILyHzgFazqVBIZuOa11Dx2vdeCnFIXm5-E5x_Dpjyu0uJId9bwcc59RyZkQN0hhW0Bf_oNtxjkP57ppiRjJgUCi-UC6OKUX07RTDzsZ9y6C9zqpdsmpLVu1NVm1TRM9vreduhxd3kj_hFEAsQCqr4RLj39v_tX22qLYpj_HOVTa1Ydxw8RvlSqmY</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Parise, Carol A.</creator><creator>Caggiano, Vincent</creator><general>Springer Science + Business Media</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3098-6160</orcidid></search><sort><creationdate>20190501</creationdate><title>Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes</title><author>Parise, Carol A. ; Caggiano, Vincent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-5f0420feee017b5177164f538cc873c803ff0bc0ea2249e348b27760b2678f443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Demographics</topic><topic>Epidemiology</topic><topic>ErbB-2 protein</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Hematology</topic><topic>Invasiveness</topic><topic>Mortality</topic><topic>Oncology</topic><topic>ORIGINAL PAPER</topic><topic>Public Health</topic><topic>Regression analysis</topic><topic>Risk</topic><topic>Survival</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parise, Carol A.</creatorcontrib><creatorcontrib>Caggiano, Vincent</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer causes & control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parise, Carol A.</au><au>Caggiano, Vincent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes</atitle><jtitle>Cancer causes & control</jtitle><stitle>Cancer Causes Control</stitle><addtitle>Cancer Causes Control</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>30</volume><issue>5</issue><spage>417</spage><epage>424</epage><pages>417-424</pages><issn>0957-5243</issn><eissn>1573-7225</eissn><abstract>Purpose
This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes.
Methods
Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2− subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2−.
Results
The odds of TP versus ER+/PR+/HER2− were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40–1.55), black (OR 1.11; CI 1.02–1.21), Asian/Pacific Islander (OR 1.15; CI 1.09–1.22), and uninsured (OR 1.42; CI 1.15–1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2− subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2− subtype.
Conclusions
Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2− subtype. However the risk of mortality between these two subtypes is similar.</abstract><cop>Cham</cop><pub>Springer Science + Business Media</pub><pmid>30879205</pmid><doi>10.1007/s10552-019-01152-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3098-6160</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0957-5243 |
| ispartof | Cancer causes & control, 2019-05, Vol.30 (5), p.417-424 |
| issn | 0957-5243 1573-7225 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2193604991 |
| source | JSTOR Archive Collection A-Z Listing; SpringerLink Journals - AutoHoldings |
| subjects | Biomedical and Life Sciences Biomedicine Breast cancer Cancer Cancer Research Demographics Epidemiology ErbB-2 protein Health risk assessment Health risks Hematology Invasiveness Mortality Oncology ORIGINAL PAPER Public Health Regression analysis Risk Survival Survival analysis |
| title | Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2– breast cancer subtypes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20clinicopatholgic%20characteristics%20and%20risk%20of%20mortality%20between%20the%20triple%20positive%20and%20ER+/PR+/HER2%E2%80%93%20breast%20cancer%20subtypes&rft.jtitle=Cancer%20causes%20&%20control&rft.au=Parise,%20Carol%20A.&rft.date=2019-05-01&rft.volume=30&rft.issue=5&rft.spage=417&rft.epage=424&rft.pages=417-424&rft.issn=0957-5243&rft.eissn=1573-7225&rft_id=info:doi/10.1007/s10552-019-01152-8&rft_dat=%3Cjstor_proqu%3E48691292%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2191941010&rft_id=info:pmid/30879205&rft_jstor_id=48691292&rfr_iscdi=true |